Part 3: Strategies for Staying on CDK4/6 Inhibitor Therapy
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Part 3: Strategies for Staying on CDK4/6 Inhibitor Therapy
-
ナレーター：
-
著者：
概要
We are pleased to present Part 3 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.
Part 3 of this series provides peer-to-peer physician perspectives on strategies for staying on CDK4/6 inhibitor therapy.
Topics include:
- Clinical trial experience managing adverse events of CDK4/6 inhibitors in early breast cancer
- Treatment persistence during real-world adjuvant CDK4/6 inhibitor therapy
Discussants:
Neil M. Iyengar, MD
Director, Survivorship Services, Winship Cancer Institute of Emory University
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA
Seth Wander, MD, PhD
Director, Precision Medicine, Termeer Center for Targeted Therapies
Director, Translational Research, Breast Oncology Program
Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA
Sponsored by Lilly